• 文献检索
  • 文档翻译
  • 深度研究
  • 学术资讯
  • Suppr Zotero 插件Zotero 插件
  • 邀请有礼
  • 套餐&价格
  • 历史记录
应用&插件
Suppr Zotero 插件Zotero 插件浏览器插件Mac 客户端Windows 客户端微信小程序
定价
高级版会员购买积分包购买API积分包
服务
文献检索文档翻译深度研究API 文档MCP 服务
关于我们
关于 Suppr公司介绍联系我们用户协议隐私条款
关注我们

Suppr 超能文献

核心技术专利:CN118964589B侵权必究
粤ICP备2023148730 号-1Suppr @ 2026

文献检索

告别复杂PubMed语法,用中文像聊天一样搜索,搜遍4000万医学文献。AI智能推荐,让科研检索更轻松。

立即免费搜索

文件翻译

保留排版,准确专业,支持PDF/Word/PPT等文件格式,支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述,25分钟生成高质量综述,智能提取关键信息,辅助科研写作。

立即免费体验

相似文献

1
Metabolic Instability of Cyanothiazolidine-Based Prolyl Oligopeptidase Inhibitors: a Structural Assignment Challenge and Potential Medicinal Chemistry Implications.基于氰噻唑烷的脯氨酰寡肽酶抑制剂的代谢不稳定性:结构归属挑战及潜在的药物化学意义
ChemMedChem. 2015 Jul;10(7):1174-83. doi: 10.1002/cmdc.201500114. Epub 2015 May 28.
2
An introduction of a pyridine group into the structure of prolyl oligopeptidase inhibitors.将吡啶基团引入脯氨酰寡肽酶抑制剂的结构中。
Bioorg Med Chem Lett. 2006 Nov 1;16(21):5590-3. doi: 10.1016/j.bmcl.2006.08.029. Epub 2006 Aug 17.
3
The prolyl oligopeptidase family.脯氨酰寡肽酶家族。
Cell Mol Life Sci. 2002 Feb;59(2):349-62. doi: 10.1007/s00018-002-8427-5.
4
Screening, purification, and characterization of an extracellular prolyl oligopeptidase from Coprinopsis clastophylla.从裂褶菌中筛选、纯化和鉴定一种细胞外脯氨酰寡肽酶。
J Microbiol. 2012 Aug;50(4):652-9. doi: 10.1007/s12275-012-2099-0. Epub 2012 Aug 25.
5
Active-Site-Directed Inhibitors of Prolyl Oligopeptidase Abolish Its Conformational Dynamics.脯氨酰寡肽酶的活性位点导向抑制剂消除其构象动力学。
Chembiochem. 2016 May 17;17(10):913-7. doi: 10.1002/cbic.201600102. Epub 2016 Mar 30.
6
Novel benzimidazole derivatives as effective inhibitors of prolyl oligopeptidase: synthesis, analysis.新型苯并咪唑衍生物作为脯氨酰寡肽酶的有效抑制剂:合成与分析。
Future Med Chem. 2024 Jan;16(1):43-58. doi: 10.4155/fmc-2023-0267. Epub 2023 Dec 6.
7
Cholinesterase and Prolyl Oligopeptidase Inhibitory Activities of Alkaloids from Argemone platyceras (Papaveraceae).罂粟科白花黄堇生物碱的胆碱酯酶和脯氨酰寡肽酶抑制活性。
Molecules. 2017 Jul 14;22(7):1181. doi: 10.3390/molecules22071181.
8
Structural revision of kynapcin-12 by total synthesis, and inhibitory activities against prolyl oligopeptidase and cancer cells.通过全合成对kynapcin-12进行结构修饰及其对脯氨酰寡肽酶和癌细胞的抑制活性。
Bioorg Med Chem Lett. 2014 Aug 1;24(15):3373-6. doi: 10.1016/j.bmcl.2014.05.091. Epub 2014 Jun 4.
9
Low barrier hydrogen bond is absent in the catalytic triads in the ground state but Is present in a transition-state complex in the prolyl oligopeptidase family of serine proteases.
J Biol Chem. 1997 Oct 10;272(41):25547-54. doi: 10.1074/jbc.272.41.25547.
10
Baicalin, a prodrug able to reach the CNS, is a prolyl oligopeptidase inhibitor.黄芩苷是一种能够进入中枢神经系统的前体药物,是脯氨酰寡肽酶抑制剂。
Bioorg Med Chem. 2008 Aug 1;16(15):7516-24. doi: 10.1016/j.bmc.2008.04.067. Epub 2008 Apr 29.

本文引用的文献

1
Development of a computational tool to rival experts in the prediction of sites of metabolism of xenobiotics by p450s.开发一种计算工具,以在预测细胞色素 P450 对外源化合物代谢部位方面与专家相媲美。
J Chem Inf Model. 2012 Sep 24;52(9):2471-83. doi: 10.1021/ci3003073. Epub 2012 Sep 4.
2
Virtual screening and computational optimization for the discovery of covalent prolyl oligopeptidase inhibitors with activity in human cells.虚拟筛选和计算优化发现具有人细胞活性的共价脯氨酰寡肽酶抑制剂。
J Med Chem. 2012 Jul 26;55(14):6306-15. doi: 10.1021/jm3002839. Epub 2012 Jul 17.
3
Integrating medicinal chemistry, organic/combinatorial chemistry, and computational chemistry for the discovery of selective estrogen receptor modulators with Forecaster, a novel platform for drug discovery.利用 Forecaster 这一新型药物发现平台,将药物化学、有机/组合化学和计算化学相结合,以发现选择性雌激素受体调节剂。
J Chem Inf Model. 2012 Jan 23;52(1):210-24. doi: 10.1021/ci2004779. Epub 2011 Dec 15.
4
Inhibitors of prolyl oligopeptidases for the therapy of human diseases: defining diseases and inhibitors.用于治疗人类疾病的脯氨酰寡肽酶抑制剂:确定疾病和抑制剂
J Med Chem. 2010 May 13;53(9):3423-38. doi: 10.1021/jm901104g.
5
Constrained peptidomimetics reveal detailed geometric requirements of covalent prolyl oligopeptidase inhibitors.受限肽模拟物揭示了共价脯氨酰寡肽酶抑制剂的详细几何要求。
J Med Chem. 2009 Nov 12;52(21):6672-84. doi: 10.1021/jm901013a.
6
Novel N-substituted 4-hydrazino piperidine derivative as a dipeptidyl peptidase IV inhibitor.新型N-取代4-肼基哌啶衍生物作为二肽基肽酶IV抑制剂
Bioorg Med Chem Lett. 2009 Sep 1;19(17):5021-5. doi: 10.1016/j.bmcl.2009.07.058. Epub 2009 Jul 12.
7
Synthesis and use of sulfonamide-, sulfoxide-, or sulfone-containing aminoglycoside-CoA bisubstrates as mechanistic probes for aminoglycoside N-6'-acetyltransferase.含磺酰胺、亚砜或砜的氨基糖苷 - 辅酶A双底物作为氨基糖苷N - 6'-乙酰转移酶机制探针的合成与应用。
Bioorg Med Chem Lett. 2008 Oct 15;18(20):5518-22. doi: 10.1016/j.bmcl.2008.09.004. Epub 2008 Sep 6.
8
Structure, function and biological relevance of prolyl oligopeptidase.脯氨酰寡肽酶的结构、功能及生物学意义
Curr Protein Pept Sci. 2008 Feb;9(1):96-107. doi: 10.2174/138920308783565723.
9
Prolyl oligopeptidase: a potential target for the treatment of cognitive disorders.脯氨酰寡肽酶:治疗认知障碍的潜在靶点。
Drug News Perspect. 2007 Jun;20(5):293-305. doi: 10.1358/dnp.2007.20.5.1120216.
10
Empirical regioselectivity models for human cytochromes P450 3A4, 2D6, and 2C9.人细胞色素P450 3A4、2D6和2C9的经验区域选择性模型
J Med Chem. 2007 Jul 12;50(14):3173-84. doi: 10.1021/jm0613471. Epub 2007 Jun 19.

基于氰噻唑烷的脯氨酰寡肽酶抑制剂的代谢不稳定性:结构归属挑战及潜在的药物化学意义

Metabolic Instability of Cyanothiazolidine-Based Prolyl Oligopeptidase Inhibitors: a Structural Assignment Challenge and Potential Medicinal Chemistry Implications.

作者信息

Schiavini Paolo, Pottel Joshua, Moitessier Nicolas, Auclair Karine

机构信息

Department of Chemistry, McGill University, 801 Sherbrooke Street West, Montréal, QC, H3A 0B8 (Canada).

出版信息

ChemMedChem. 2015 Jul;10(7):1174-83. doi: 10.1002/cmdc.201500114. Epub 2015 May 28.

DOI:10.1002/cmdc.201500114
PMID:26018317
原文链接:https://pmc.ncbi.nlm.nih.gov/articles/PMC5177022/
Abstract

As part of the development of cyanothiazolidine-based prolyl oligopeptidase inhibitors, initial metabolism studies suggested multiple sites of oxidation by P450 enzymes. Surprisingly, in-depth investigations revealed that epimerization at multiple stereogenic centers was responsible for the conversion of the single primary metabolite into a panel of secondary metabolites. The rapid isomerization of all seven detected molecules precluded the use of NMR spectroscopy or X-ray crystallography for complete structural determination, presenting an interesting structure elucidation challenge. Through a combination of LC-MS analysis, synthetic work, deuterium exchange studies, and computational predictions, we were able to characterize all metabolites and to elucidate their dynamic behavior in solution. In the context of drug development, this study reveals that cyanothiazolidine moieties are problematic due to their rapid P450-mediated oxidation and the unpredictable stability of the corresponding metabolites.

摘要

作为基于氰噻唑烷的脯氨酰寡肽酶抑制剂开发的一部分,初步代谢研究表明存在多个被细胞色素P450酶氧化的位点。令人惊讶的是,深入研究发现多个手性中心的差向异构化导致单一主要代谢物转化为一系列次要代谢物。所有七个检测到的分子的快速异构化使得无法使用核磁共振光谱或X射线晶体学进行完整的结构测定,这带来了一个有趣的结构解析挑战。通过液相色谱-质谱分析、合成工作、氘交换研究和计算预测相结合,我们能够表征所有代谢物并阐明它们在溶液中的动态行为。在药物开发的背景下,这项研究表明氰噻唑烷部分存在问题,因为它们会通过细胞色素P450介导快速氧化,且相应代谢物的稳定性不可预测。

https://cdn.ncbi.nlm.nih.gov/pmc/blobs/b22d/5177022/f5ea724c5b00/nihms6373f11.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/b22d/5177022/c7661b9806a2/nihms6373f1.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/b22d/5177022/9be1e98a6bd4/nihms6373f2.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/b22d/5177022/6c2e039b14d3/nihms6373f3.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/b22d/5177022/94f3f81caefc/nihms6373f4.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/b22d/5177022/9eec6262ba73/nihms6373f5.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/b22d/5177022/0646582e80e6/nihms6373f6.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/b22d/5177022/b68178a9a5ce/nihms6373f7.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/b22d/5177022/ca5b04d85990/nihms6373f8.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/b22d/5177022/a57b24281e68/nihms6373f9.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/b22d/5177022/d6cc5d3c2e13/nihms6373f10.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/b22d/5177022/f5ea724c5b00/nihms6373f11.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/b22d/5177022/c7661b9806a2/nihms6373f1.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/b22d/5177022/9be1e98a6bd4/nihms6373f2.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/b22d/5177022/6c2e039b14d3/nihms6373f3.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/b22d/5177022/94f3f81caefc/nihms6373f4.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/b22d/5177022/9eec6262ba73/nihms6373f5.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/b22d/5177022/0646582e80e6/nihms6373f6.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/b22d/5177022/b68178a9a5ce/nihms6373f7.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/b22d/5177022/ca5b04d85990/nihms6373f8.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/b22d/5177022/a57b24281e68/nihms6373f9.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/b22d/5177022/d6cc5d3c2e13/nihms6373f10.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/b22d/5177022/f5ea724c5b00/nihms6373f11.jpg